Loading stock data…
BMRA
$2.19+0.01 (+0.46%)
Market ClosedLast close May 1
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Biomerica, Inc. in the Healthcare sector is trading at $2.19. The stock is currently near its 52-week low of $1.87, remaining 15.8% below its 200-day moving average. Technical signals show neutral RSI of 68 and bullish MACD crossover, explaining why BMRA maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 68) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.19
Potential Upside
5%
Whystock Fair Value$2.30
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnosti...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.64M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.20
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-112.13%
Volume
Today's trading volume
5,507
Recent News
How Biomerica Deal Expands Henry Schein’s (HSIC) Diagnostic Ambitions and Alters Its Investment Narrative
In October 2025, Biomerica announced a marketing services arrangement with Henry Schein to promote its inFoods IBS test throughout the United States, excluding New York State, utilizing Henry Schein's network of more than 400 sales representatives targeting primary care and gastroenterology practices. This collaboration highlights Henry Schein's evolving presence in precision diagnostics, following clinical evidence for the inFoods test published in a leading gastrointestinal journal showing...
Biomerica receives approval in UAE for at-home ulcer test
The company is collaborating with local companies and healthcare providers to distribute the ulcer test.